Reported / Citable
Background
Named plaintiffs Mohammad Bozorgi, Ken Calderone, and Manohar K. Rao filed a securities fraud class action against Cassava Sciences, Inc. and four executives, alleging a fraudulent scheme to mislead investors about simufilam, an investigational Alzheimer’s drug. The complaint alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5, claiming plaintiffs purchased Cassava securities between September 14, 2020 and July 26, 2022 and suffered damages from defendants’ misstatements and omissions.
On August 18, 2021, a Citizen Petition filed with the FDA accused Cassava of research misconduct related to simufilam. The SEC and DOJ subsequently began investigating and requested documents from Cassava. Defendants filed a motion to dismiss in October 2022, which triggered the Private Securities Litigation Reform Act’s (PSLRA) mandatory automatic stay of all discovery pending resolution of that motion.
Plaintiffs moved to partially lift the discovery stay to obtain documents Cassava had produced in a related Delaware derivative action and materials Cassava had provided to the SEC, DOJ, and National Institutes of Health. Plaintiffs argued they would be “unduly prejudiced” by remaining at an informational disadvantage and risked losing settlement opportunities if Cassava’s limited resources were depleted by the government investigations.